Patents Represented by Attorney, Agent or Law Firm D. Byron Miller
-
Patent number: 6175763Abstract: An electrotransport system (20) for delivery of a drug through the skin (63) of a patient includes a tactile signal generator (36) for generating and transmitting a tactile signal to the skin of a patient upon the occurrence of an event associated with the operation of the system. The tactile signal may be an electric AC signaling current (Sr, Sp) applied through the skin, ie, an electric current different from the therapeutic electrotransport drive current. The electric signaling current is preferably a pulsed current of sufficient frequency and amplitude to allow the patient to feel it. The tactile signal may alternatively be generated by an electromechanical device in contact with the skin such as a piezoelectric vibrating element or magnetodynamic element such as a solenoid driven pin. The waveform of the tactile signaling current preferably has a zero average current component such that no net therapeutic drug is delivered by the tactile signal current.Type: GrantFiled: March 29, 1996Date of Patent: January 16, 2001Assignee: Alza CorporationInventors: Paul D. Sorenson, Gary A. Lattin, Larry A. McNichols
-
Patent number: 6171294Abstract: The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (eg, fentanyl hydrochloride) dispersed in a hydrogel formulation for use in an electrotransport device (10). In accordance with one aspect of the invention, the concentration of fentanyl/sufentanil in the donor reservoir (26) solution is above a predetermined minimum concentration, whereby the transdermal electrotransport flux of fentanyl/sufentanil is maintained independent of the concentration of fentanyl/sufentanil in solution. In accordance with a second aspect of the present invention, the donor reservoir (26) of the electrotransport delivery device (10) is comprised of silver and the donor reservoir (26) contains a predetermined “excess” loading of fentanyl/sufentanil halide to prevent silver ion migration with attendant skin discoloration.Type: GrantFiled: July 10, 1997Date of Patent: January 9, 2001Assignee: ALZA CorporationInventors: Mary Southam, Keith J. Bernstein, Henk Noorduin
-
Patent number: 6163720Abstract: The disclosed invention relates to an improved electrotransport device. The improvement relates to a membrane assembly including a low porosity membrane adhered or sealed to one or two high porosity membranes. The high porosity membranes protect the low porosity membrane from being damaged by components or contaminates on the body surface and/or in the drug reservoir which can lead to undesirable passive flux and/or insufficient iontophoretic flux. As a result, the electrotransport device having the membrane assembly more reliably, precisely, and accurately delivers drug and/or therapeutic agent through the body surface by electrotransport.Type: GrantFiled: December 3, 1998Date of Patent: December 19, 2000Assignee: Alza CorporationInventors: J. Richard Gyory, Ronald P. Haak
-
Patent number: 6136327Abstract: Preferential delivery via electrotransport of a preferred isomeric form of a pharmaceutically active chiral compound from a mixture of the isomeric forms of said compound is provided. A method of decreasing the delivery via electrotransport of a less preferred isomer of a drug is also provided. Drug delivery devices suitable for such preferential delivery and methods of making the same are also provided.Type: GrantFiled: December 1, 1997Date of Patent: October 24, 2000Assignee: ALZA CorporationInventors: Suneel K. Gupta, Gayatri Sathyan, Rama Padmanabhan
-
Patent number: 6090095Abstract: An electrotransport delivery device (410) includes control circuitry for discontinuously delivering a beneficial agent (eg, a drug) through a body surface (eg, skin 400). For example, the device may be the type which is manually activated by the patient or other medical personnel to activate electrotransport drug delivery. Once electrotransport delivery has been activated, a timer (221) counts a transition interval, typically about one minute, during which the device is allowed to operate and the impedance of the body surface (400) is allowed to stabilize. Thereafter, the electrotransport current and voltage are then monitored and compared to predetermined limits. Allowing for the transition interval permits tighter tolerances in monitoring the applied current.Type: GrantFiled: June 24, 1997Date of Patent: July 18, 2000Assignee: ALZA CorporationInventors: Larry A. McNichols, John D. Badzinski, Ronald P. Haak
-
Patent number: 6091975Abstract: An agent detecting device comprising a plate (6) having a plurality of microprotrusions (4) for piercing the skin of a patient. Each of the microprotrusions (4) having an electrode (14, 16 and 18) thereon for detecting the presence of an agent in the patient's interstitial fluid.Type: GrantFiled: April 1, 1998Date of Patent: July 18, 2000Assignee: Alza CorporationInventors: Peter E. Daddona, Gregory T. Fieldson, Avtar S. Nat, Wei-Qi Lin
-
Patent number: 6086572Abstract: A two-part electrotransport drug delivery device (20) is comprised of a controller (22) which has a plurality of different electronic outputs. The controller (22) is adapted to be mechanically and electrically coupled to a plurality of different drug-containing units (24). Each drug unit (24) includes a means (40, 42, Rx, Cx) for signaling the controller (22). The signal is read by the controller (22) and a predetermined electronic output is thereby selected and applied through the drug unit (24) in order to deliver the drug contained therein by electrotransport. The signal sent by the drug unit (24) to the controller (22) may be an optical signal (e.g., reflected light), a signal sent by an electro-mechanical connector, an electrical signal (e.g., resistance or capacitance), a magnetic signal or a metal detector sensing signal.Type: GrantFiled: March 9, 1998Date of Patent: July 11, 2000Assignee: ALZA CorporationInventors: Susan A. Johnson, Gary A. Lattin, Larry A. McNichols
-
Patent number: 6083196Abstract: A device (3) comprising a sheet member (6) having a plurality of microprotrusions (4) for penetrating the skin and a substantially incompressible agent reservoir housing (15) contacting and extending across the sheet member (6) for transmitting a hold-down force applied the sheet member (6) to maintain the microprotrusions (4) in skin-piercing relation to the skin, even during and after normal patient body movement.Type: GrantFiled: December 9, 1998Date of Patent: July 4, 2000Assignee: ALZA CorporationInventors: Joseph Creagan Trautman, Michel J. N. Cormier, Hyunok Lynn Kim, Michael G. Zuck
-
Patent number: 6071508Abstract: A method is provided for preparing drug formulations suitable for electrotransport drug delivery. The drug to be delivered, present in salt form, is contacted with an ion exchange material prior to incorporation into the reservoir (26) of an electrotransport delivery system (10). In this way, the drug salt is partially or completely neutralized. This technique is useful for adjusting the pH of the drug formulation without incorporating extraneous materials, e.g., competing ions or the like, into the reservoir (26).Type: GrantFiled: December 18, 1997Date of Patent: June 6, 2000Assignee: Alza CorporationInventor: Thomas Owen Murdock
-
Patent number: 6057374Abstract: An electrotransport drug-containing composition is provided. The composition includes a drug to be delivered through a body surface (eg, skin) of a patient, and a permeation enhancer which is solid or semisolid at temperatures typically encountered during storage of pharmaceuticals (eg, temperatures up to at least about 25.degree. C.). The composition of the invention may be applied from a device 10 suitable for electrotransport delivery. A method for increasing electrotransport agent delivery rate and reducing body surface resistance relies on applying the composition of the invention to the body surface, and applying an electric current through the composition and the body surface.Type: GrantFiled: December 5, 1997Date of Patent: May 2, 2000Assignee: Alza CorporationInventors: James A. Huntington, Michel Cormier
-
Patent number: 6050988Abstract: A device (2) comprising a sheet member (6) having a plurality of microprotrusions (4) extending from a bottom edge (5) for penetrating the skin of a patient. The sheet member (6) when in use being oriented in an approximately perpendicular relation to the patient's skin.Type: GrantFiled: December 9, 1998Date of Patent: April 18, 2000Assignee: ALZA CorporationInventor: Michael G. Zuck
-
Patent number: 6049733Abstract: An electrotransport apparatus using dispersed ion exchange material (19,83) is disclosed. The ion exchange material (19,83) may be dispersed in either the donor electrode assembly (10), the counter electrode assembly (10) or both electrode assemblies. The dispersed ion exchange material (83) comprises mobile ionic species (84-2) and substantially immobile ionic species (P). The dispersed ion exchange material (83, 84-2) interacts with competitive species (86) generated during electrotransport to render those species substantially immobile (87). Electrotransport devices exhibiting reduced polarization are also disclosed.Type: GrantFiled: September 26, 1997Date of Patent: April 11, 2000Assignee: ALZA CorporationInventors: J. Bradley Phipps, Lyn C. Moodie, J. Richard Gyory, Felix Theeuwes
-
Patent number: 6039977Abstract: Pharmaceutical hydrogel formulations containing polyvinyl alcohol are provided. The formulations may serve as rug reservoirs in electrotransport drug delivery systems or passive transdermal systems, or they may be used in a variety of other types of dosage forms, e.g., capsules, suppositories, aerosols, and the like. With these formulations, there is virtually no syneresis encountered upon long term storage, an advantage that derives from selecting the quantity of polyvinyl alcohol in the gel to correspond to the polymer's degree of hydrolysis.Type: GrantFiled: December 9, 1997Date of Patent: March 21, 2000Assignee: Alza CorporationInventors: Subramanian S. Venkatraman, Thomas O. Murdock, Stephanus Pudjijanto
-
Patent number: 5993435Abstract: A selectively permeable membrane (14) is positioned between the agent reservoir (15) and the electrode (11) of a donor electrode assembly (8) in an iontophoretic delivery device (10). Optionally, an electrolyte reservoir (13) is positioned intermediate the electrode (11) and the agent reservoir (15). In certain embodiments, the membrane (14) is permeable to species of less than a predetermined molecular weight and substantially less permeable to species of greater than the predetermined molecular weight. The agent is capable of dissociating into agent ions and counter ions.Type: GrantFiled: August 24, 1998Date of Patent: November 30, 1999Assignee: ALZA CorporationInventors: Ronald P. Haak, J. Richard Gyory, Felix Theeuwes
-
Patent number: 5995869Abstract: A device and method are provided for reducing or preventing skin sensitization in electrotransport drug delivery. The method involves co-administration of a countersensitizing agent, comprising cis-urocanic acid or an analog thereof, with the drug delivered via electrotransport. Novel drug reservoirs and electrotransport drug delivery systems, formulated with a countersensitizing agent as described herein, are provided as well.Type: GrantFiled: June 11, 1997Date of Patent: November 30, 1999Assignee: Alza CorporationInventors: Michel J. N. Cormier, James A. Matriano, Ronald P. Haak, Peter E. Daddona
-
Patent number: 5990179Abstract: A composition suitable for transdermal electrotransport delivery of an agent through a body surface comprises a free acid/base form of an agent to be delivered by transdermal electrotransport, and a salt form of the agent, and optionally a permeation enhancer. Methods of enhancing transdermal electrotransport delivery and of forming a composition for the enhancement of transdermal electrotransport drug delivery, and a transdermal electrotransport delivery device (10) utilizing the compositions of the invention are disclosed.Type: GrantFiled: April 28, 1995Date of Patent: November 23, 1999Assignee: ALZA CorporationInventors: J. Richard Gyory, Patricia S. Campbell
-
Patent number: 5985316Abstract: An electrotransport device (10) for transdermal delivery of an agent through a body surface has a donor reservoir (16) which contains a compound formed of the agent and a transdermal permeation enhancer, the compound being able to dissociate into an agent ion and an enhancer counter ion. Methods of enhancing transdermal electrotransport drug delivery and methods of forming a composition exhibiting enhanced transdermal electrotransport drug delivery are also provided.Type: GrantFiled: April 28, 1995Date of Patent: November 16, 1999Assignee: Alza CorporationInventors: J. Richard Gyory, Patricia S. Campbell
-
Patent number: 5978701Abstract: A two-part electrotransport drug delivery device (20) is comprised of a controller (22) which has a plurality of different electronic outputs. The controller (22) is adapted to be mechanically and electrically coupled to a plurality of different drug-containing units (24). Each drug unit (24) includes a means (40, 42, Rx, Cx) for signaling the controller (22). The signal is read by the controller (22) and a predetermined electronic output is thereby selected and applied through the drug unit (24) in order to deliver the drug contained therein by electrotransport. The signal sent by the drug unit (24) to the controller (22) may be an optical signal (eg, reflected light), a signal sent by an electro-mechanical connector, an electrical signal (eg, resistance or capacitance), a magnetic signal or a metal detector sensing signal.Type: GrantFiled: June 2, 1995Date of Patent: November 2, 1999Assignee: ALZA CorporationInventors: Susan A. Johnson, Gary A. Lattin, Larry A. McNichols
-
Patent number: 5941844Abstract: A method encompasses the substantially continuous electrotransport delivery of luteinizing hormone releasing hormone (LHRH), prologues, analogues, salts or mixtures thereof, preferably at a substantially constant rate, to a female mammal for the purpose of modifying its reproductive cycle. An electrotransport device substantially is suited for the continuous delivery of LHRH prologues, analogues, salts or mixtures thereof over an extended period of time to a mammal. The present technology may be successfully applied to the controlled breeding of mammals, such as thoroughbred race horses.Type: GrantFiled: November 17, 1997Date of Patent: August 24, 1999Assignee: ALZA CorporationInventor: James B. Eckenhoff, deceased
-
Patent number: 5919155Abstract: A device (10) for the electrically assisted delivery of a therapeutic agent is described. The device (10) has rigid zones or regions (12, 14) which are physically connected by a flexible means (16) such as a web. The flexible means (16) permits the rigid zones (12, 14) to move independently with respect to each other while remaining physically connected or coupled. In a preferred embodiment, the rigid zones are physically and electronically coupled by the flexible means. In another embodiment, the device (500) comprises one or more rigid zones, the skin side of the rigid zone having a radius of curvature (520) which approximates that of the body site to which the device (500) is to be attached. A method of increasing the body surface conformability of an electrotransport device (50, 150, 170) is described. The method involves the step of intentionally placing rigid subcomponents (58, 36, 37) of the device in physically separate zones (52, 54; 152, 154, 156, 158; 172, 174, 176, 178) within the device.Type: GrantFiled: January 18, 1995Date of Patent: July 6, 1999Assignee: ALZA CorporationInventors: Gary A. Lattin, J. Richard Gyory, Charles Albert, Scott Jay Gilbert